Quantification of the dependencies of the Bragg peak degradation due to lung tissue in proton therapy on a CT-based lung tumor phantom.
The fine, sub-millimeter sized structure of lung tissue causes a degradation of the Bragg peak curve in particle therapy. The Bragg peak is degraded because particles of the same energy traverse lung tissue of different compositions of high and low density materials. Hence, they experience different energy losses resulting in variable ranges and a broadened Bragg peak. Since this fine structure of lung tissue is not resolved in standard treatment-planning CTs, current state-of-the-art dose calculation procedures used in the clinical routine are unable to account for this degradation. Neglecting this Bragg peak degradation in treatment planning can lead to an underdose in the target volume and an overdose distal to the target. Aim of this work is to systematically investigate the potential effects of the Bragg peak degradation on the dose distribution in dependence of different parameters like the tumor volume and its depth in lung. Proton plans were optimized on CT based phantoms without considering the Bragg peak degradation and afterwards recalculated with the Monte Carlo toolkit TOPAS: first, without consideration of the degradation and second, with the Bragg peak degradation accounted for. The direct comparison of these two dose distributions enables a quantification of the degradation effect. To carve out the dependencies of various parameters that could influence the Bragg peak degradation and thus the target dose, the simulations were performed for a variety of tumor sizes and shapes, as well as different positions within the lung. The results show that due to the Bragg peak degradation the mean dose in the target volume can be reduced by a few percent up to 14% (for extreme cases) depending on the geometry. It was shown that this effect increases with a decreasing tumor volume and increasing depth of the tumor. For the first time, a tumor specific estimation of the effect on the dose distribution due to the Bragg peak degradation in lung tissue is presented.